152 related articles for article (PubMed ID: 32918950)
1. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.
Katz NK; Barohn RJ
Neuropharmacology; 2021 Jan; 182():108303. PubMed ID: 32918950
[TBL] [Abstract][Full Text] [Related]
2. Mary Broadfoot Walker (1888-1974): a historic discovery in myasthenia gravis.
Pearce JM
Eur Neurol; 2005; 53(1):51-3. PubMed ID: 15746548
[TBL] [Abstract][Full Text] [Related]
3. Mary Broadfoot Walker: 83 years since a historical discovery.
Carvalho VM; Nogueira EAG; Rosa GR; Fragoso YD
Arq Neuropsiquiatr; 2017 Nov; 75(11):825-826. PubMed ID: 29236828
[TBL] [Abstract][Full Text] [Related]
4. Contemporary opinions about Mary Walker: a shy pioneer of therapeutic neurology.
Keesey JC
Neurology; 1998 Nov; 51(5):1433-9. PubMed ID: 9818874
[TBL] [Abstract][Full Text] [Related]
5. [Opus posthumous].
Kotsias BA
Medicina (B Aires); 2017; 77(5):440-441. PubMed ID: 29044026
[No Abstract] [Full Text] [Related]
6. Mary Broadfoot Walker (1888-1974).
Johnston JD
J Neurol; 2007 Sep; 254(9):1306-7. PubMed ID: 18000738
[No Abstract] [Full Text] [Related]
7. The miracle at St Alfege's: seventy years on.
Lee MR
J R Soc Med; 2007 Feb; 100(2):108-9. PubMed ID: 17277286
[No Abstract] [Full Text] [Related]
8. The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London.
Johnston JD
J Hist Neurosci; 2005 Jun; 14(2):121-37. PubMed ID: 16019657
[TBL] [Abstract][Full Text] [Related]
9. The Mary Walker effect: Mary Broadfoot Walker.
McCarter SJ; Burkholder DB; Klaas JP; Martinez-Thompson JM; Boes CJ
J R Coll Physicians Edinb; 2019 Sep; 49(3):255-259. PubMed ID: 31497797
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis and arrows of fortune.
Morowitz HJ
Hosp Pract (Off Ed); 1986 Mar; 21(3):179-82, 184, 189-90 passim. PubMed ID: 3005351
[No Abstract] [Full Text] [Related]
11. Dr Lazar Remen (1907-74): a forgotten pioneer in the treatment of myasthenia gravis.
Ohry A
J Med Biogr; 2009 May; 17(2):73-4. PubMed ID: 19401508
[TBL] [Abstract][Full Text] [Related]
12. The miracle at St Alfege's: seventy years on.
O'Brien MD
J R Soc Med; 2007 Jun; 100(6):257. PubMed ID: 17541091
[No Abstract] [Full Text] [Related]
13. The history of myasthenia gravis.
Pascuzzi RM
Neurol Clin; 1994 May; 12(2):231-42. PubMed ID: 8041339
[TBL] [Abstract][Full Text] [Related]
14. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.
Yu QS; Holloway HW; Luo W; Lahiri DK; Brossi A; Greig NH
Bioorg Med Chem; 2010 Jul; 18(13):4687-93. PubMed ID: 20627738
[TBL] [Abstract][Full Text] [Related]
15. Episodes in the story of physostigmine.
Scheindlin S
Mol Interv; 2010 Feb; 10(1):4-10. PubMed ID: 20124558
[No Abstract] [Full Text] [Related]
16. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
Mehndiratta MM; Pandey S; Kuntzer T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
[TBL] [Abstract][Full Text] [Related]
17. Slow-binding inhibitors of acetylcholinesterase of medical interest.
Lushchekina SV; Masson P
Neuropharmacology; 2020 Oct; 177():108236. PubMed ID: 32712274
[TBL] [Abstract][Full Text] [Related]
18. "Crisis" in myasthenia gravis: an historical perspective.
Keesey JC
Muscle Nerve; 2002 Jul; 26(1):1-3. PubMed ID: 12115943
[No Abstract] [Full Text] [Related]
19. The history of the introduction of curare into medicine.
Bennett AE
Anesth Analg; 1968; 47(5):484-92. PubMed ID: 4876882
[No Abstract] [Full Text] [Related]
20. [Historical view on the development of knowledge about myasthenia gravis. (Introduction to a symposium)].
Hausmanowa-Petrusewicz I
Neurol Neurochir Pol; 1970; 4(3):261-4. PubMed ID: 4917026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
